Table 1.
Mouse models of asthma, acute versus chronic.
| Strain | Allergen | Sensitization | Exposure/Challenge | Pulmonary Inflammation | References |
|---|---|---|---|---|---|
| BALB/c | OVA | OVA (IP) on 7 alternate days | OVA aerosol for 8 consecutive days | Acute | [52,53] |
| BALB/c | OVA | OVA (IP) on 7 alternate days | OVA (IT) on day 42 for 3 days, each 3 days apart | Acute | [54] |
| BALB/c | OVA | OVA + AlOH3 (IP) on day 0 and OVA (IP) on day 10 | OVA aerosol on days 17 and 24 | Acute | [55] |
| BALB/c | OVA | OVA + AlOH3 (IP) on days 0 and 5 | 2 × OVA inhalations, each 4 h apart on day 17 | Acute | [56] |
| BALB/c | OVA | OVA + alum (IP) on days 0 and 14 | OVA (IN) on days 14, 25, 26, and 27 | Acute | [57] |
| BALB/c | OVA | OVA + AlOH3 (IP) on days 0 and 14 | OVA aerosol on days 28–30 | Acute | [58,59] |
| BALB/c | OVA | OVA/alum (IP) on days 0 and 12 | OVA aerosol on days 18–23 | Acute | [60,61,62] |
| BALB/c | OVA | OVA + alum (IP) on days 0 and 14 | OVA aerosol on days 28–30 and 72 days after last challenge | Acute | [63] |
| BALB/c | OVA + LPS | OVA-specific Th1 (IV) | Day 1 OVA (IN) daily for 4 days, last treatment day LPS (IN) | Acute | [49] |
| BALB/c | OVA | OVA (IT) on day −1, day 0 Th17 retro-orbital | Day 1–3 daily OVA (IT) | Acute | [50] |
| C57BL/6 | HDM | Der p 1 + AlOH3 (IP) on day 0 | HDM aerosol on day 14 for 7 consecutive days | Acute | [64] |
| C57BL/6 | OVA + LPS | OVA + LPS (OP) on days 0 and 7 | OVA (OP) on days 14–16 | Acute | [65] |
| A/J | Bla g 2 and Der f 1 | Ova + AlOH3 (IP) on days 0 and 7 | Allergen oro-tracheal on day 14 | Acute | [66] |
| C57BL/6 | OVA | OVA-DCs (IT) on day 0 | OVA aerosol on day 14–20 | Acute | [67] |
| CB.17 SCID | Dpt | Human PBMCs (IP) | Dpt aerosols 1×/day for 4 consecutive days starting day 14 | Acute | [46] |
| NOD/SCID | HDM | Human PBMCs (IP) | Dpt (IT) on days 1, 3, 7 | Acute | [47] |
| BALB/c | OVA | Ova + AlOH3 (IP) on days 0 and 5 | OVA aerosol 3 days/week, starting day 17, for 6 weeks | Chronic | [56] |
| BALB/c | OVA | OVA + alum (IP) on days 7 and 21 | OVA exposure 3 days/week, for up to 8 weeks | Chronic | [68] |
| BALB/c | OVA | OVA + alum (IP) on days 0 and 14 | OVA (IN) on days 14, 27, 28, 47, 61, and 73–75 | Chronic | [69] |
| BALB/c | OVA | OVA + aluminum potassium sulphate (IP) on days 1 and 11 | OVA (IN) on days 11, 19, 20, 33, 34, 47, 48, 61, 62, 75, 76, 89, 90 | Chronic | [70] |
| BALB/c | OVA | OVA + alum (IP) on days 0 and 12 | OVA aerosol on days 18–23 and then 3 days/week for up to 8 weeks starting on day 26 | Chronic | [62] |
| BALB/c | OVA | OVA + alum (SC) on days 0, 7, 14, 21 | OVA (IN) on days 27, 29, 31, and then 2×/week for 3 months | Chronic | [71] |
| BALB/c | HDM | NA | HDM (IN) 5 days/week for up to 7 weeks | Chronic | [27] |
| BALB/c | HDM | NA | HDM (IN) 5 days/week for up to 5 weeks | Chronic | [28] |
IP = intraperitoneal, IN = intranasal, IT = intratracheal, SC = subcutaneous, IV = intravenous, OP = oropharyngeal aspiration, NA = not applicable.